Details checkedClinical trial listing onlyCheckedregistry

City of Hope Pedmark adult testicular-cancer otoprotection study

Also known as: Sodium Thiosulfate Anhydrous, Pedmark, Disodium Thiosulfate, NCT07218913, NCI-2025-07298, 25407

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 1

Status

Active

Target Gene

—

Route / Mode

Intravenous infusion

Confidence

82%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

United States

Population

adult, cisplatin-ototoxicity, testicular-cancer, otoprotection, pedmark

Trial IDs

Mechanism

Intravenous Pedmark/sodium thiosulfate administered 6 hours after cisplatin to reduce cisplatin-induced ototoxicity in adult men receiving cisplatin-based chemotherapy for metastatic testicular germ cell tumors.

Indications

Hearing Loss Cisplatin-Induced Hearing Loss Ototoxicity

Notes

Verified as a City of Hope/NCI-sponsored Phase 1 study testing Pedmark in adult metastatic testicular germ-cell tumor patients receiving cisplatin. Pedmark is a marketed Fennec product, but the registry lists this trial as institution-led; do not classify City of Hope as a company.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, allCompanies, isIndustrySponsored, stage, status, route, indications...

IDs: NCT07218913, NCI-2025-07298, 25407, Pedmark

Open

Key Events

2025-10-21

City of Hope Pedmark adult cisplatin otoprotection study first posted

2026-04-17

ClinicalTrials.gov update lists the Pedmark adult study as recruiting

Clinical Trials (1)